Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial
Abstract
AR‐V7‐positive metastatic prostate cancer is a lethal phenotype with few treatment options and poor survival.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 26, 2021
- Source ID
- 10.1002/pros.24110
Entities
People
- Adam Jendrisak
- Alice Jordan
- Charles G Drake
- Donna Dowling
- Drew M Pardoll
- Emmanuel S. Antonarakis
- Eugene Shenderov
- Hao Wang
- James R. Eshleman
- Joseph Schonhoft
- Jun Luo
- Karim Boudadi
- Mario A. Eisenberger
- Michael A. Carducci
- Rana Harb
- Rana Sullivan
- Wei Fu
Organizations
- Bristol-Myers Squibb
- Columbia University
- Johns Hopkins University
- National Institutes of Health
- Prostate Cancer Foundation
- United States Department of Defense